Approval · Notice of Compliance 8644 · 2007
COZAAR: Notice of Compliance 8644
Issued March 13, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8644
- Date
- March 13, 2007
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: cozaar is also indicated in patients with essential hypertension and left ventricular hypertrophy; the inclusion of the life study and other revisions to the product monograph.
- Therapeutic class
- Angiotensin ii receptor antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COZAAR | Not yet assigned | — |
Medicinal ingredients
- LOSARTAN POTASSIUM 25 MG per TAB
- LOSARTAN POTASSIUM 50 MG per TAB
- LOSARTAN POTASSIUM 100 MG per TAB